Response assessment in acute myeloid leukemia by flow cytometry supersedes cytomorphology at time of aplasia, amends cases without molecular residual disease marker and serves as an independent prognostic marker at time of aplasia and post-induction.
作者信息
Köhnke Thomas, Bücklein Veit, Rechkemmer Sandra, Schneider Stephanie, Rothenberg-Thurley Maja, Metzeler Klaus H, Sauerland Maria-Cristina, Hiddemann Wolfgang, Spiekermann Karsten, Subklewe Marion
机构信息
Laboratory for Leukemia Diagnostics, Department of Medicine III, University Hospital, LMU Munich, Munich.
Translational Cancer Immunology, Gene Center, LMU Munich, Munich.
出版信息
Haematologica. 2019 Nov;104(11):e510-e513. doi: 10.3324/haematol.2018.215236. Epub 2019 Apr 4.
Abstract
摘要
相似文献
1
Response assessment in acute myeloid leukemia by flow cytometry supersedes cytomorphology at time of aplasia, amends cases without molecular residual disease marker and serves as an independent prognostic marker at time of aplasia and post-induction.流式细胞术对急性髓系白血病的缓解评估在再生障碍时取代了细胞形态学，修正了无分子残留病标志物的病例，并在再生障碍时和诱导后作为独立的预后标志物。
Haematologica. 2019 Nov;104(11):e510-e513. doi: 10.3324/haematol.2018.215236. Epub 2019 Apr 4.
2
Prognostic impact of minimal residual disease analysis by flow cytometry in patients with acute myeloid leukemia before and after allogeneic hemopoietic stem cell transplantation.流式细胞术检测微小残留病对急性髓系白血病患者异基因造血干细胞移植前后的预后影响
Eur J Haematol. 2014 Sep;93(3):239-46. doi: 10.1111/ejh.12336. Epub 2014 Apr 29.
3
Acute myeloid leukemia measurable residual disease detection by flow cytometry in peripheral blood vs bone marrow.通过流式细胞术检测外周血与骨髓中急性髓系白血病的可测量残留病
Blood. 2021 Jan 28;137(4):569-572. doi: 10.1182/blood.2020006219.
4
Bone marrow evaluation for diagnosis and monitoring of acute myeloid leukemia.用于急性髓系白血病诊断和监测的骨髓评估
Blood Rev. 2017 Jul;31(4):185-192. doi: 10.1016/j.blre.2017.01.003. Epub 2017 Feb 2.
5
Optimal Measurable Residual Disease Testing for Acute Myeloid Leukemia.急性髓系白血病的最佳可测量残留病检测
Surg Pathol Clin. 2019 Sep;12(3):671-686. doi: 10.1016/j.path.2019.03.009. Epub 2019 May 18.
6
[Quantification of minimal residual disease by multiparameter flow cytometry in acute myeloid leukemia. From diagnosis to prognosis].[急性髓系白血病中通过多参数流式细胞术对微小残留病的定量分析。从诊断到预后]
Med Klin (Munich). 2005 Jan 15;100(1):54-9. doi: 10.1007/s00063-005-1122-1.
7
Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia.用于检测急性髓系白血病中可测量残留病和白血病干细胞的骨髓采样与处理综合方案。
J Vis Exp. 2018 Mar 5(133):56386. doi: 10.3791/56386.
8
Residual disease monitoring in childhood acute myeloid leukemia by multiparameter flow cytometry: the MRD-AML-BFM Study Group.多参数流式细胞术监测儿童急性髓系白血病残留病：MRD-AML-BFM研究组
J Clin Oncol. 2006 Aug 1;24(22):3686-92. doi: 10.1200/JCO.2005.05.4312.
9
Prognostic value of multicenter flow cytometry harmonized assessment of minimal residual disease in acute myeloblastic leukemia.多中心流式细胞术统一评估急性髓细胞白血病微小残留病的预后价值
Hematol Oncol. 2018 Apr;36(2):422-428. doi: 10.1002/hon.2488. Epub 2017 Dec 7.
10
CD25 expression on residual leukemic blasts at the time of allogeneic hematopoietic stem cell transplant predicts relapse in patients with acute myeloid leukemia without complete remission.异基因造血干细胞移植时残留白血病原始细胞上的CD25表达可预测急性髓系白血病未完全缓解患者的复发情况。
Leuk Lymphoma. 2016;57(6):1375-81. doi: 10.3109/10428194.2015.1099644. Epub 2015 Dec 23.
引用本文的文献
1
Prognostic significance of blast immunophenotype on first post-induction bone marrow biopsy.诱导缓解后首次骨髓活检时原始细胞免疫表型的预后意义
Leuk Lymphoma. 2023 Mar;64(3):750-752. doi: 10.1080/10428194.2023.2172981. Epub 2023 Feb 1.
2
Reproducible measurable residual disease detection by multiparametric flow cytometry in acute myeloid leukemia.多参数流式细胞术检测急性髓细胞白血病可重现的有测量价值残留病灶。
Leukemia. 2022 Sep;36(9):2208-2217. doi: 10.1038/s41375-022-01647-5. Epub 2022 Jul 18.
本文引用的文献
1
Sequential high-dose cytarabine and mitoxantrone (S-HAM) versus standard double induction in acute myeloid leukemia-a phase 3 study.序贯大剂量阿糖胞苷和米托蒽醌（S-HAM）与标准双诱导治疗急性髓系白血病的比较：一项 3 期研究。
Leukemia. 2018 Dec;32(12):2558-2571. doi: 10.1038/s41375-018-0268-9. Epub 2018 Oct 1.
2
Molecular Minimal Residual Disease in Acute Myeloid Leukemia.急性髓系白血病的分子微小残留病。
N Engl J Med. 2018 Mar 29;378(13):1189-1199. doi: 10.1056/NEJMoa1716863.
3
Flow cytometric demonstration of decrease in bone marrow leukemic blasts after 'Day 14' without further therapy in acute myeloid leukemia.急性髓系白血病患者在“第14天”后未经进一步治疗，流式细胞术显示骨髓白血病原始细胞减少。
Leuk Lymphoma. 2017 Nov;58(11):2717-2719. doi: 10.1080/10428194.2017.1307359. Epub 2017 Mar 28.
4
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.成人急性髓系白血病的诊断与管理：2017年国际专家小组的欧洲白血病网络（ELN）建议
Blood. 2017 Jan 26;129(4):424-447. doi: 10.1182/blood-2016-08-733196. Epub 2016 Nov 28.
5
Effect of genetic profiling on prediction of therapeutic resistance and survival in adult acute myeloid leukemia.基因谱分析对成人急性髓系白血病治疗耐药性预测及生存的影响。
Leukemia. 2015 Oct;29(10):2104-7. doi: 10.1038/leu.2015.76. Epub 2015 Mar 16.
6
Early assessment of minimal residual disease in AML by flow cytometry during aplasia identifies patients at increased risk of relapse.流式细胞术在细胞减少期检测 AML 微小残留病可识别复发风险增加的患者。
Leukemia. 2015 Feb;29(2):377-86. doi: 10.1038/leu.2014.186. Epub 2014 Jun 10.
7
Prognostic relevance of treatment response measured by flow cytometric residual disease detection in older patients with acute myeloid leukemia.流式细胞术残留病检测评估老年急性髓系白血病患者治疗反应的预后相关性。
J Clin Oncol. 2013 Nov 10;31(32):4123-31. doi: 10.1200/JCO.2013.49.1753. Epub 2013 Sep 23.
8
High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study.流式细胞术微小残留病检测对急性髓系白血病具有高度预后影响：HOVON/SAKK AML 42A 研究数据。
J Clin Oncol. 2013 Nov 1;31(31):3889-97. doi: 10.1200/JCO.2012.45.9628. Epub 2013 Sep 23.
9
Comparative analysis of different approaches to measure treatment response in acute myeloid leukemia.比较分析急性髓细胞白血病治疗反应不同评估方法。
J Clin Oncol. 2012 Oct 10;30(29):3625-32. doi: 10.1200/JCO.2011.41.5323. Epub 2012 Sep 10.
10
Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial.缓解诱导治疗早期清除原始细胞是急性髓系白血病实现完全缓解和长期预后的主要独立预后因素：来自德国急性髓系白血病协作组（AMLCG）1992年试验的数据。
Blood. 2003 Jan 1;101(1):64-70. doi: 10.1182/blood-2002-02-0532. Epub 2002 Jun 28.
Zotero 插件